| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Short Communications |
From the Institute of Pathology/Tumor Immunology,*
University of Regensburg, Regensburg, Germany; Pharmaceutical Research
Gene Technology,
F. Hoffmann-LaRoche, Basel,
Switzerland; and the Institute of Pathology,
Technical University Dresden, Dresden, Germany
Activation of endothelial cells, fibrin deposition, and coagulation within the tumor vasculature has been shown in vivo to correlate with the occurrence of tumor necrosis factor (TNF)-induced tumor necrosis in mice. In the present study we investigated which target cells mediate the TNF-induced necrosis in fibrosarcomas grown in wild type (wt), TNF receptor type 1-deficient (TNFRp55-/-), and TNF receptor type 2-deficient (TNFRp75-/-) mice. TNF administration resulted in tumor necrosis exclusively in wt and TNFRp75-/-, but not in TNFRp55-/- mice, indicating a dependence of TNF-mediated tumor necrosis on the expression of TNF receptor type 1. However, using wt and TNFRp55-/- fibrosarcomas in wt mice, we found that TNF-mediated tumor necrosis was completely independent of TNF receptor type 1 expression in tumor cells. Thus we could exclude any direct tumoricidal effect of TNF in this model. Soluble TNF induced leukostasis in wt and TNFRp75-/- mice but not in TNFRp55-/- mice. TNF-induced leukostasis in TNFRp55-/- mice was restored by adoptive bone marrow transplantation of wt hematopoietic cells, but TNF failed to induce tumor necrosis in these chimeric mice. Because TNF administration resulted in both activation and focal damage of tumor endothelium, TNF receptor type 1-expressing cells of the tumor vasculature, likely to be endothelial cells, appear to be target cells for mediating TNF-induced tumor necrosis.
This article has been cited by other articles:
 |
|
 |
|
  X. Zhao, M. Mohaupt, J. Jiang, S. Liu, B. Li, and Z. Qin Tumor Necrosis Factor Receptor 2-Mediated Tumor Suppression Is Nitric Oxide Dependent and Involves Angiostasis Cancer Res., May 1, 2007; 67(9): 4443 - 4450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wang, N. Li, H. Li, B. Liu, J. Qiu, T. Chen, and X. Cao Silencing of Human Phosphatidylethanolamine-Binding Protein 4 Sensitizes Breast Cancer Cells to Tumor Necrosis Factor-{alpha}-Induced Apoptosis and Cell Growth Arrest Clin. Cancer Res., October 15, 2005; 11(20): 7545 - 7553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Dienst, A. Grunow, M. Unruh, B. Rabausch, J. E. Nor, J. W. U. Fries, and C. Gottstein Specific Occlusion of Murine and Human Tumor Vasculature by VCAM-1-Targeted Recombinant Fusion Proteins J Natl Cancer Inst, May 18, 2005; 97(10): 733 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Gerl and D. L. Vaux Apoptosis in the development and treatment of cancer Carcinogenesis, February 1, 2005; 26(2): 263 - 270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mocellin, M. Provenzano, C. R. Rossi, P. Pilati, R. Scalerta, M. Lise, and D. Nitti Induction of Endothelial Nitric Oxide Synthase Expression by Melanoma Sensitizes Endothelial Cells to Tumor Necrosis Factor-Driven Cytotoxicity Clin. Cancer Res., October 15, 2004; 10(20): 6879 - 6886. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Schwamberger, P. Hammerl, E. Ferber, M. Freudenberg, and C. Galanos TNF revisited: TNF-independent antitumor activity in sera of mice sensitized with Propionibacterium acnes and challenged with lipopolysaccharide J. Leukoc. Biol., December 1, 2003; 74(6): 1056 - 1063. [Abstract] [Full Text]
|
|
|
|
|
|
P. Monti, B. E. Leone, F. Marchesi, G. Balzano, A. Zerbi, F. Scaltrini, C. Pasquali, G. Calori, F. Pessi, C. Sperti, et al. The CC Chemokine MCP-1/CCL2 in Pancreatic Cancer Progression: Regulation of Expression and Potential Mechanisms of Antimalignant Activity Cancer Res., November 1, 2003; 63(21): 7451 - 7461. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. C. Manegold, J. Hutter, S. A. Pahernik, K. Messmer, and M. Dellian Platelet-endothelial interaction in tumor angiogenesis and microcirculation Blood, March 1, 2003; 101(5): 1970 - 1976. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Stoelcker, T. Hehlgans, K. Weigl, H. Bluethmann, G. E. Grau, and D. N. Mannel Requirement for Tumor Necrosis Factor Receptor 2 Expression on Vascular Cells To Induce Experimental Cerebral Malaria Infect. Immun., October 1, 2002; 70(10): 5857 - 5859. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-H. Shen, J.-H. Zhou, S. R. Broussard, G. G. Freund, R. Dantzer, and K. W. Kelley Proinflammatory Cytokines Block Growth of Breast Cancer Cells by Impairing Signals from a Growth Factor Receptor Cancer Res., August 15, 2002; 62(16): 4746 - 4756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hehlgans, B. Stoelcker, P. Stopfer, P. Muller, G. Cernaianu, M. Guba, M. Steinbauer, S. A. Nedospasov, K. Pfeffer, and D. N. Mannel Lymphotoxin-{beta} Receptor Immune Interaction Promotes Tumor Growth by Inducing Angiogenesis Cancer Res., July 15, 2002; 62(14): 4034 - 4040. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hallermalm, K. Seki, C. Wei, C. Castelli, L. Rivoltini, R. Kiessling, and J. Levitskaya Tumor necrosis factor-{alpha} induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface Blood, August 15, 2001; 98(4): 1108 - 1115. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
